中度低温与正常体温对接受静脉-动脉体外膜氧合的心源性休克患者30天死亡率的影响:一项随机临床试验
这项在法国20个心脏休克中心进行的随机临床试验,纳入374例接受静脉-动脉体外膜氧合(VA-ECMO)的心源性休克患者,比较早期中度低温(33-34 °C)24小时与严格正常体温(36-37 °C)的效果。主要结局30天死亡率在两组间无显著差异(42% vs 51%;调整比值比0.71,95%CI 0.45-1.13,P=0.15)。作者认为,由于95%CI较宽且包含潜在重要效应,这些发现应被视为不确定。
要点
- 早期中度低温(33-34 °C)24小时未显著改善接受VA-ECMO的心源性休克患者30天生存。
- 30天死亡率:中度低温组42% vs 正常体温组51%,调整比值比0.71(95%CI 0.45-1.13,P=0.15)。
- 31项次要结局中30项不确定,复合结局调整比值比0.61(95%CI 0.39-0.96,P=0.03)。
核心结论
- 在接受静脉-动脉体外膜氧合治疗的难治性心源性休克患者中,早期应用24小时中度低温与正常体温相比未显著提高生存率。
- 由于95%CI较宽且包含潜在重要效应,这些发现应被视为不确定。
研究设计与样本
- 随机临床试验,在法国20个心脏休克中心的ICU进行,纳入条件为已气管插管并因心源性休克接受静脉-动脉体外膜氧合不足6小时的患者,时间为2016年10月至2019年7月。
- 786例合格患者中374例被随机分组,334例完成试验并纳入主要分析(平均年龄58岁[SD 12],24%为女性)。
- 干预为早期中度低温(33-34 °C;n=168)24小时或严格正常体温(36-37 °C;n=166)。
- 主要结局为30天死亡率,次要结局共31项,包括第7、60、180天死亡率及复合结局等。
- 最终随访于2019年11月进行。
主要发现
- 30天时,中度低温组71例(42%)死亡,正常体温组84例(51%)死亡(调整比值比0.71[95%CI 0.45-1.13],P=0.15;风险差-8.3%[95%CI -16.3%至-0.3%])。
- 第30天死亡、心脏移植、升级至左心室辅助装置植入或卒中的复合结局,中度低温组相比正常体温组的调整比值比为0.61(95%CI 0.39-0.96;P=0.03),风险差为-11.5%(95%CI -23.2%至0.2%)。
- 31项次要结局中30项不确定。
- 中度或严重出血发生率:中度低温组41% vs 正常体温组42%;感染发生率两组均为52%;菌血症发生率:中度低温组20% vs 正常体温组30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出95%CI较宽且包含潜在重要效应,这些发现应被视为不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal approach to the use of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiogenic shock is uncertain. OBJECTIVE: To determine whether early use of moderate hypothermia (33-34 °C) compared with strict normothermia (36-37 °C) improves mortality in patients with cardiogenic shock receiving venoarterial ECMO. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of patients (who were eligible if they had been endotracheally intubated and were receiving venoarterial ECMO for cardiogenic shock for <6 hours) conducted in the intensive care units at 20 French cardiac shock care centers between October 2016 and July 2019. Of 786 eligible patients, 374 were randomized. Final follow-up occurred in November 2019. INTERVENTIONS: Early moderate hypothermia (33-34 °C; n = 168) for 24 hours or strict normothermia (36-37 °C; n = 166). MAIN OUTCOMES AND MEASURES: The primary outcome was mortality at 30 days. There were 31 secondary outcomes including mortality at days 7, 60, and 180; a composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at days 30, 60, and 180; and days without requiring a ventilator or kidney replacement therapy at days 30, 60, and 180. Adverse events included rates of severe bleeding, sepsis, and number of units of packed red blood cells transfused during venoarterial ECMO. RESULTS: Among the 374 patients who were randomized, 334 completed the trial (mean age, 58 [SD, 12] years; 24% women) and were included in the primary analysis. At 30 days, 71 patients (42%) in the moderate hypothermia group had died vs 84 patients (51%) in the normothermia group (adjusted odds ratio, 0.71 [95% CI, 0.45 to 1.13], P = .15; risk difference, -8.3% [95% CI, -16.3% to -0.3%]). For the composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at day 30, the adjusted odds ratio was 0.61 (95% CI, 0.39 to 0.96; P = .03) for the moderate hypothermia group compared with the normothermia group and the risk difference was -11.5% (95% CI, -23.2% to 0.2%). Of the 31 secondary outcomes, 30 were inconclusive. The incidence of moderate or severe bleeding was 41% in the moderate hypothermia group vs 42% in the normothermia group. The incidence of infections was 52% in both groups. The incidence of bacteremia was 20% in the moderate hypothermia group vs 30% in the normothermia group. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial involving patients with refractory cardiogenic shock treated with venoarterial ECMO, early application of moderate hypothermia for 24 hours did not significantly increase survival compared with normothermia. However, because the 95% CI was wide and included a potentially important effect size, these findings should be considered inconclusive. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02754193.
引用
- Levy B, Girerd N, Amour J, et al. Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial. JAMA. 2022. PMID: 35103766. doi:10.1001/jama.2021.24776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。